Human CD95, also known as Fas or APO-1, is a cell-surface death receptor belonging to the tumor necrosis factor receptor (TNFR) superfamily. CD95 plays a central role in the regulation of programmed cell death. Upon binding to its natural ligand, CD95 ligand (CD95L/FasL), CD95 undergoes receptor oligomerization and initiates the formation of the death-inducing signaling complex (DISC), leading to activation of downstream caspases and apoptosis.

A human CD95 blocking antibody is a neutralizing antibody designed to specifically bind CD95 and inhibit the interaction between CD95 and its ligand, CD95L. By blocking CD95-mediated signaling, the antibody can prevent or reduce Fas-dependent apoptotic signaling and is therefore a valuable tool for investigating the biological functions of the CD95/CD95L pathway.

Human CD95 blocking antibodies are widely used in research involving apoptosis, immune-cell regulation, immune tolerance, inflammation, and cancer biology. They can be used to study CD95-dependent signaling pathways and to evaluate the effects of CD95-mediated apoptosis in cellular and molecular assays. The specific blocking activity and optimal experimental conditions depend on the antibody clone, binding epitope, and application.